An injection for double chin reduction developed by Kythera Biopharmaceutical Inc was unanimously backed by an independent panel of experts on Monday, bringing the drug a step closer to approval by the U.S. Food and Drug Administration.
Submental fat, known colloqially as a “double chin” can be caused by a plethora of factors including genetics and lifestyle, and can be resistant to diet and exercise.

ATX-101 would be non-surgical option, represent new category for company. The drug is widely expected to win approval by May 13, when the FDA is scheduled to make its final decision. Read more